Merck & Co., Inc.: enforcement record and regulatory exposure
Merck & Co., Inc. scores 36 out of 100 on the RedFlag Index™ (October 2026), ranking #10 of ten tracked companies, with 3 documented cases of which 1 remain open.
Documented record
Merck has paid more than $10.7 billion in tracked penalties since 2000.
2011–2012: Merck paid $950 million and pleaded guilty to illegally promoting Vioxx, including a $321.6 million criminal fine.
2008: Merck paid $650 million over pricing and kickback allegations involving Zocor, Vioxx, and Pepcid.
RegulationWatch coverage
- Off-Label Promotion
Merck's Vioxx penalty was $950 million. It arrived eight years after the drug was pulled.
Merck pleaded guilty to a misdemeanor. It did not admit the civil allegations about cardiovascular safety.
- Drug Pricing
Federal judge rejects Merck's constitutional challenge to Medicare drug price negotiation
Judge Colleen Kollar-Kotelly of the US District Court for the District of Columbia rejected Merck's First and Fifth Amendment challenge to the Inflation Reduction Act's Medicare drug price negotiation programme. Merck filed the first industry challenge to the programme in June 2023.
